Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations

BACKGROUND: Tyrosine-kinase inhibitors (TKIs) have become the cornerstone treatment of patients with non-small cell lung cancer that harbor oncogenic EGFR mutations. The counterpart of these drugs is the financial burden that they impose, which often creates a barrier for accessing treatment in deve...

Descripción completa

Detalles Bibliográficos
Autores principales: Arrieta, Oscar, Catalán, Rodrigo, Guzmán-Vazquez, Silvia, Barrón, Feliciano, Lara-Mejía, Luis, Soto-Molina, Herman, Ramos-Ramírez, Maritza, Flores-Estrada, Diana, de la Garza, Jaime
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465360/
https://www.ncbi.nlm.nih.gov/pubmed/32873256
http://dx.doi.org/10.1186/s12885-020-07329-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465360/
https://www.ncbi.nlm.nih.gov/pubmed/32873256
http://dx.doi.org/10.1186/s12885-020-07329-8

Ejemplares similares